106 related articles for article (PubMed ID: 19751801)
1. Telomerase in cancer immunotherapy.
Liu JP; Chen W; Schwarer AP; Li H
Biochim Biophys Acta; 2010 Jan; 1805(1):35-42. PubMed ID: 19751801
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.
Zareian N; Eremin O; Pandha H; Baird R; Kwatra V; Funingana G; Verma C; Choy D; Hargreaves S; Moghimi P; Shepherd A; Lobo DN; Eremin J; Farzaneh F; Kordasti S; Spicer J
Exp Biol Med (Maywood); 2024; 249():10021. PubMed ID: 38463391
[TBL] [Abstract][Full Text] [Related]
3. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients.
Maecker B; von Bergwelt-Baildon MS; Anderson KS; Vonderheide RH; Anderson KC; Nadler LM; Schultze JL
Clin Exp Immunol; 2005 Sep; 141(3):558-62. PubMed ID: 16045747
[TBL] [Abstract][Full Text] [Related]
4. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G
Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors.
Choi W; Lee Y; Choi BK; Park BM; Kim YH; Yun T; Lee WJ; Yoo H; Baek JY; Woo SM; Lim MC; Kwon BS
Cytotherapy; 2023 Nov; 25(11):1236-1241. PubMed ID: 37632518
[TBL] [Abstract][Full Text] [Related]
6. Immortalization of human and rhesus macaque primary antigen-specific T cells by retrovirally transduced telomerase reverse transcriptase.
Barsov EV
Curr Protoc Immunol; 2011 Nov; Chapter 7():Unit 7.21B. PubMed ID: 22048804
[TBL] [Abstract][Full Text] [Related]
7. Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?
Valmori D; Ayyoub M
PLoS Med; 2004 Nov; 1(2):e26. PubMed ID: 15578104
[TBL] [Abstract][Full Text] [Related]
8. The bright side of chemistry: Exploring synthetic peptide-based anticancer vaccines.
D'Aniello A; Del Bene A; Mottola S; Mazzarella V; Cutolo R; Campagna E; Di Maro S; Messere A
J Pept Sci; 2024 Apr; ():e3596. PubMed ID: 38571326
[TBL] [Abstract][Full Text] [Related]
9. A second chance for telomerase reverse transcriptase in anticancer immunotherapy.
Zanetti M
Nat Rev Clin Oncol; 2017 Feb; 14(2):115-128. PubMed ID: 27245281
[TBL] [Abstract][Full Text] [Related]
10. Recent patents on anti-telomerase cancer therapy.
Agrawal A; Dang S; Gabrani R
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):102-17. PubMed ID: 21854360
[TBL] [Abstract][Full Text] [Related]
11. Telomerase-Targeted Cancer Immunotherapy.
Mizukoshi E; Kaneko S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013796
[TBL] [Abstract][Full Text] [Related]
12. Specific association of human telomerase activity with immortal cells and cancer.
Kim NW; Piatyszek MA; Prowse KR; Harley CB; West MD; Ho PL; Coviello GM; Wright WE; Weinrich SL; Shay JW
Science; 1994 Dec; 266(5193):2011-5. PubMed ID: 7605428
[TBL] [Abstract][Full Text] [Related]
13. Telomerase based anticancer immunotherapy and vaccines approaches.
Kailashiya C; Sharma HB; Kailashiya J
Vaccine; 2017 Oct; 35(43):5768-5775. PubMed ID: 28893481
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Analysis of the Clinical Characteristics of Patients with Breast Cancer Treated with Telomerase Peptide Immunotherapy Combined with Cytotoxic Chemotherapy.
Kim JY; Yang DW; Kim S; Choi JG
Breast Cancer (Dove Med Press); 2023; 15():955-966. PubMed ID: 38146419
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: Constructive Approach for Breast Cancer Treatment.
Anayyat U; Ahad F; Muluh TA; Zaidi SAA; Usmani F; Yang H; Li M; Hassan HA; Wang X
Breast Cancer (Dove Med Press); 2023; 15():925-951. PubMed ID: 38116189
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations.
Tornesello ML; Cerasuolo A; Starita N; Amiranda S; Bonelli P; Tuccillo FM; Buonaguro FM; Buonaguro L; Tornesello AL
Front Cell Dev Biol; 2023; 11():1286683. PubMed ID: 38033865
[TBL] [Abstract][Full Text] [Related]
17. Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA).
Ali JH; Walter M
Cancer Cell Int; 2023 Sep; 23(1):197. PubMed ID: 37679807
[TBL] [Abstract][Full Text] [Related]
18. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy.
Mokhtari RB; Sambi M; Qorri B; Baluch N; Ashayeri N; Kumar S; Cheng HM; Yeger H; Das B; Szewczuk MR
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298809
[TBL] [Abstract][Full Text] [Related]
19. HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.
von Witzleben A; Wang C; Laban S; Savelyeva N; Ottensmeier CH
Cells; 2020 Sep; 9(9):. PubMed ID: 32942747
[TBL] [Abstract][Full Text] [Related]
20. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Carlson RD; Flickinger JC; Snook AE
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
